カイダ　ケンイチ   KAIDA Kenichi   海田　賢一    所属   埼玉医科大学  医学部 総合医療センター　脳神経内科    職種   教授
論文種別	学術雑誌(原著)
言語種別	英語
査読の有無	査読あり
表題	Efficacy and Safety of Rituximab in Refractory CIDP With or Without IgG4 Autoantibodies (RECIPE): Protocol for a Double-Blind, Randomized, Placebo-Controlled Clinical Trial
掲載誌名	正式名：JMIR Research Protocols
出版社	JMIR Publications Inc.
巻・号・頁	9(4),e17117-e17117頁
著者・共著者	Shinobu Shimizu,Masahiro Iijima,Yuki Fukami,Natsuko Tamura,Masahiro Nakatochi,Masahiko Ando,Ryoji Nishi,Haruki Koike,Kenichi Kaida,Michiaki Koga,Takashi Kanda,Hidenori Ogata,Jun-Ichi Kira,Masahiro Mori,Satoshi Kuwabara,Masahisa Katsuno
発行年月	2020/04
概要	<sec><title>Background</title>Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated peripheral neuropathy that is currently classified into several clinical subtypes, which are presumed to have different pathogenic mechanisms. Recently, studies identified a subgroup of patients with CIDP who were positive for IgG4 autoantibodies against paranodal proteins, such as neurofascin-155 and contactin-1, who respond poorly to first-line therapies for typical CIDP, including intravenous immunoglobulin therapy.</sec><sec><title>Objective</title>This study aims to evaluate the efficacy and safety of intravenous rituximab according to IgG4 autoantibody status in patients with refractory CIDP.</sec><sec><title>Methods</title>The Evaluation of the Efficacy and Safety of Rituximab in Refractory CIDP Patients with IgG4 Autoantibodies in the Exploratory Clinical (RECIPE) trial consists of 2 cohorts: a multicenter, placebo-controlled, randomized study cohort of 15 patients with IgG4 autoantibody-positive CIDP (rituximab:placebo = 2:1) and an open-label trial cohort of 10 patients with antibody-negative CIDP. The primary endpoint is improvement
DOI	10.2196/17117
PMID	32234705